Abstract
Background: Silencing of two or more complementary signaling pathways can lead to cell death, while loss of any single genetic function does not show a severe phnotype, this kind of inter action is coined as “synthetic lethality”. Nowadays, synthetic lethality has become a widely used anti-cancer strategy.
Method: We reviewed the synthetic lethal interactions exploited in anticancer therapies before 2016. Conclusion: Synthetic lethality is a well proved anticancer strategy and more synthetic lethal interactions is being translated into clinical cancer therapies.Keywords: Synthetic lethality, targeted therapy, PARP inhibitors, drug resistance, cancer therapy, signaling pathways.
Graphical Abstract
Current Cancer Drug Targets
Title:Synthetic Lethal Interactions in Cancer Therapy
Volume: 17 Issue: 4
Author(s): Xinwei Geng, Xiaohui Wang, Dan Zhu*Songmin Ying*
Affiliation:
- Department of Respiratory Medicine, Jinhua Municipal Central Hospital, Jinhua Hospital of Zhejiang University, Jinhua,China
- Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital, Institute of Respiratory Diseases, Zhejiang University School of Medicine, Hangzhou,China
Keywords: Synthetic lethality, targeted therapy, PARP inhibitors, drug resistance, cancer therapy, signaling pathways.
Abstract: Background: Silencing of two or more complementary signaling pathways can lead to cell death, while loss of any single genetic function does not show a severe phnotype, this kind of inter action is coined as “synthetic lethality”. Nowadays, synthetic lethality has become a widely used anti-cancer strategy.
Method: We reviewed the synthetic lethal interactions exploited in anticancer therapies before 2016. Conclusion: Synthetic lethality is a well proved anticancer strategy and more synthetic lethal interactions is being translated into clinical cancer therapies.Export Options
About this article
Cite this article as:
Geng Xinwei, Wang Xiaohui, Zhu Dan*, Ying Songmin*, Synthetic Lethal Interactions in Cancer Therapy, Current Cancer Drug Targets 2017; 17 (4) . https://dx.doi.org/10.2174/1568009616666160426122736
DOI https://dx.doi.org/10.2174/1568009616666160426122736 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Transcriptionally Targeted Adenovirus Vectors
Current Gene Therapy Heteromerization of G Protein-Coupled Receptors: Relevance to Neurological Disorders and Neurotherapeutics
CNS & Neurological Disorders - Drug Targets MicroRNAs in Neuroblastoma: Biomarkers with Therapeutic Potential
Current Medicinal Chemistry The Role of ABC Transporters in Protecting Cells from Bilirubin Toxicity
Current Pharmaceutical Design Involvement of Cannabinoids in Cellular Proliferation
Mini-Reviews in Medicinal Chemistry Recent Highlights on Molecular Hybrids Potentially Useful in Central Nervous System Disorders
Mini-Reviews in Medicinal Chemistry Pharmacological Applications of Lignins and Lignins Related Compounds: An Overview
Current Organic Chemistry Carbon Nano Tubes: Novel Drug Delivery System in Amelioration of Alzheimer’s Disease
Combinatorial Chemistry & High Throughput Screening Metallothioneins and Cancer
Current Protein & Peptide Science Resveratrol and Neurodegenerative Diseases: Activation of SIRT1 as the Potential Pathway towards Neuroprotection
Current Neurovascular Research Are Retinoids a Promise for Alzheimer’s Disease Management?
Current Medicinal Chemistry Physiological Functions of Presenilins; Beyond γ-Secretase
Current Pharmaceutical Biotechnology Small Molecule Tyrosine Kinase Inhibitors: Potential Role in Pediatric Malignant Solid Tumors
Current Cancer Drug Targets The Association of Palmitoylethanolamide with Luteolin Decreases Neuroinflammation and Stimulates Autophagy in Parkinson's Disease Model
CNS & Neurological Disorders - Drug Targets Pluripotent Stem Cell-Derived Somatic Stem Cells as Tool to Study the Role of MicroRNAs in Early Human Neural Development
Current Molecular Medicine Neuroprotection by Association of Palmitoylethanolamide with Luteolin in Experimental Alzheimer’s Disease Models: The Control of Neuroinflammation
CNS & Neurological Disorders - Drug Targets HSV Amplicons: Neuro Applications
Current Gene Therapy Synthesis and Cholinesterase Inhibitory Activity of N-Phosphorylated/ N-Tiophosphorylated Tacrine
Medicinal Chemistry Long Noncoding RNA MALAT1: Insights into its Biogenesis and Implications in Human Disease
Current Pharmaceutical Design Effects of Vitamin A Deficiency and Opioids on Parvalbumin + Interneurons in the Hippocampus of the HIV-1 Transgenic Rat
Current HIV Research